Trials / Completed
CompletedNCT05691699
A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults
A Phase 1 First in Human, Single and Multiple Ascending Dose and Food Effect and Drug-Drug Interaction in Healthy Subjects to Evaluate the Safety, Tolerability and Assessment of Pharmacokinetics of ABBV-903
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 104 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate adverse events and tolerability of single and multiple doses of ABBV-903, and to assess how the drug moves through the body in healthy adult volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABBV-903 | Capsule; oral |
| DRUG | Placebo for ABBV-903 | Capsule; oral |
| DRUG | Itraconazole | Capsule; oral |
Timeline
- Start date
- 2023-01-03
- Primary completion
- 2023-10-23
- Completion
- 2023-10-23
- First posted
- 2023-01-20
- Last updated
- 2023-10-30
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05691699. Inclusion in this directory is not an endorsement.